## ACHC: Acadia Healthcare Company, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.32 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($12.67)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Bearish (Bullish: 0, Bearish: 3)

**1. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Acadia Healthcare Company, Inc. (ACHC) and Encourages Investors to Learn More About the Investigation**
- Source: CW39 Houston | 20251215T160936 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential securities claims against Acadia Healthcare Company, Inc. (ACHC) after the company disclosed higher anticipated expenses for patient-related litigation, leading to a reduction in its full-year 2025 Adjusted EBITDA guidance. Investors who purchased Acadia securities are encouraged to contact the law firm to learn more and potentially assist in the investigation. The firm operates on a contingency fee basis for class actions.

**2. Acadia Healthcare Company, Inc. (ACHC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation**
- Source: CBS 17 | 20251216T210931 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Acadia Healthcare Company, Inc. (NASDAQ:ACHC) on behalf of investors. The investigation follows Acadia's disclosure of higher anticipated patient-related litigation costs, leading to a reduction in its full-year 2025 Adjusted EBITDA guidance. Investors who purchased Acadia securities are encouraged to contact the law firm to learn more about the ongoing investigation.

**3. Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Acadia Healthcare Company, Inc. (ACHC) and Encourages Investors to Learn More About the Investigation**
- Source: KLBK | 20251216T160839 | Bearish | Relevance: 100%
- Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Acadia Healthcare Company, Inc. (ACHC) concerning potential corporate wrongdoing by its officers and/or directors. The firm is encouraging investors who purchased Acadia Healthcare securities before February 28, 2020, and still hold them, to join the investigation. Interested investors can find more information or assist by visiting bgandg.com/ACHC.

### Analyst Activity

**Target Signal:** VERY_BEARISH (Raises: 0, Lowers: 9)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | Barclays | $14 | $17 | -18% |
| 2025-12-03 | RBC Capital | $19 | $22 | -14% |
| 2025-12-03 | Cantor Fitzgera | $17 | $22 | -23% |
| 2025-12-03 | Keybanc | $25 | $30 | -17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | Barclays | main | Equal-Weight |
| 2025-12-03 | RBC Capital | main | Outperform |
| 2025-12-03 | Cantor Fitzgera | main | Neutral |
| 2025-12-03 | Keybanc | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 1 ($0.02M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 65.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 9 / 0 |

**Top Holders:**
- Blackrock Inc.: 11.9% (+20.4%)
- Vanguard Group Inc: 10.2% (+7.8%)
- Wellington Managemen: 10.2% (+11.8%)
- FMR, LLC: 6.6% (+2.2%)
- Khrom Capital Manage: 5.5% (+103.0%)

### Key Risks

1. High short interest (18.7%, 5.5 days to cover): squeeze risk or crowded bearish bet.
2. Long-term trend broken: trading 35.9% below SMA200.
3. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.32 suggests fair value with growth premium. Analyst sentiment negative (9 target cuts vs 0 raises). Institutional flow bullish (9 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $1.3B |
| Beta | 0.90 |
| 52W Range | $12.63 - $47.08 |
| Short Interest | 18.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.32 |
| Forward P/E | 7.4 |
| Current P/E | 7.0 |
| YoY Growth | -5.3% |
| EPS Direction | FALLING |

### Technicals

MRS_20 strengthening from -8.0% to -1.9% (+6.1% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.9pp (needs >4.0% for momentum thesis). MRS_5 turning positive (3.0%) - potential reversal signal. AM_20 at -3.8% indicates price below own 20MA trend. Underperforming sector by 3.6pp, stock-specific weakness. Below SMA200 (0.64x), long-term trend not supportive. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.90% (CS: 17) | Neutral |
| RSI_14 | 37.3 | Neutral |
| MACD Histogram | 0.18 | Bullish |
| vs SMA20 | 0.962x | Below |
| vs SMA50 | 0.765x | Below |
| vs SMA200 | 0.641x | Below |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $14.53
- **Stop Loss:** $12.67 (12.8% risk)
- **Target:** $18.25 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 580
- **Position Value:** $8,427.40
- **Portfolio %:** 8.43%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-26 (Est: $0.13)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.66 | $0.72 | +9.2% |
| 2025Q2 | $0.71 | $0.83 | +17.4% |
| 2025Q1 | $0.36 | $0.40 | +12.0% |
| 2024Q4 | $0.71 | $0.64 | -10.4% |

---
*RULE-based L3 | 2026-01-07 01:41 | MRS_20*